How does Poseida Therapeutics Inc. (PSTX) change from a tortoise to a hare?

Poseida Therapeutics Inc. (NASDAQ: PSTX) stock fell -2.00% on Friday to $4.42 against a previous-day closing price of $4.51. With 7.85 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.15 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.5000 whereas the lowest price it dropped to was $3.8500. The 52-week range on PSTX shows that it touched its highest point at $11.10 and its lowest point at $1.82 during that stretch. It currently has a 1-year price target of $16.25.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PSTX was up-trending over the past week, with a rise of 76.10%, but this was up by 66.17% over a month. Three-month performance surged to 45.39% while six-month performance fell -3.07%. The stock lost -45.02% in the past year, while it has lost -35.10% so far this year. A look at the trailing 12-month EPS for PSTX yields -2.32 with Next year EPS estimates of -3.26. For the next quarter, that number is -0.77. This implies an EPS growth rate of 4.30% for this year and -3.40% for next year.

Float and Shares Shorts:

At present, 62.56 million PSTX shares are outstanding with a float of 37.10 million shares on hand for trading. On Jul 14, 2022, short shares totaled 1.8 million, which was 2.87% higher than short shares on Jun 14, 2022. In addition to Dr. Eric M. Ostertag M.D., Ph.D. as the firm’s Exec. Chairman, Mr. Mark J. Gergen J.D. serves as its CEO & Director.

Institutional Ownership:

Through their ownership of 43.58% of PSTX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 32.05% of PSTX, in contrast to 21.02% held by mutual funds. Shares owned by individuals account for 17.74%. As the largest shareholder in PSTX with 14.94% of the stake, Fidelity Management & Research Co holds 9,367,864 shares worth 9,367,864. A second-largest stockholder of PSTX, Pentwater Capital Management LP, holds 4,967,227 shares, controlling over 7.92% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in PSTX, holding 1,937,880 shares or 3.09% stake. With a 3.28% stake in PSTX, the Fidelity Growth Company Fund is the largest stakeholder. A total of 2,057,812 shares are owned by the mutual fund manager. The Fidelity Select Port. – Health Ca, which owns about 2.79% of PSTX stock, is the second-largest Mutual Fund holder. It holds 1,746,425 shares valued at 4.51 million. Fidelity Advisor Health Care Fund holds 1.64% of the stake in PSTX, owning 1,025,220 shares worth 2.65 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PSTX since 5 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PSTX analysts setting a high price target of $24.00 and a low target of $9.00, the average target price over the next 12 months is $16.25. Based on these targets, PSTX could surge 442.99% to reach the target high and rise by 103.62% to reach the target low. Reaching the average price target will result in a growth of 267.65% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. PSTX will report FY 2022 earnings on 03/09/2023. Analysts have provided yearly estimates in a range of -$2.57 being high and -$3.70 being low. For PSTX, this leads to a yearly average estimate of -$3.34. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Poseida Therapeutics Inc. surprised analysts by -$0.20 when it reported -$0.93 EPS against a consensus estimate of -$0.73. The surprise factor in the prior quarter was $0.37. Based on analyst estimates, the high estimate for the next quarter is -$0.57 and the low estimate is -$0.86. The average estimate for the next quarter is thus -$0.77.

Summary of Insider Activity:

Insiders traded PSTX stock several times over the past three months with 5 Buys and 0 Sells. In these transactions, 117,900 shares were bought while 0 shares were sold. The number of buy transactions has increased to 36 while that of sell transactions has risen to 13 over the past year. The total number of shares bought during that period was 1,756,700 while 338,221 shares were sold.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]